JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Raises Price Target to $31
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
JP Morgan analyst Brian Cheng maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and raises the price target from $30 to $31.
JP Morgan analyst Brian Cheng maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and raises the price target from $30 to $31.